A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

114

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Acne Vulgaris
Interventions
DRUG

Olumacostat Glasaretil Gel, 7.5%

Gel containing Olumacostat Glasaretil

OTHER

Olumacostat Glasaretil Gel, Vehicle

Vehicle (placebo) gel

Trial Locations (12)

V3R 6A7

Guildford Dermatology Specialist Inc, Surrey

L4M 6L2

Ultranova Skincare, Barrie

L3P1A8

Lynderm Research Inc, Markham

L6J 7W5

Institute of Cosmetic & Laser Surgery, Oakville

K9J 1Z2

Skin Centre for Dermatology, Peterborough

L4B 1A5

The Centre for Dermatology, Richmond Hill

M5S 3B4

Research Toronto, Toronto

N2J 1C4

K. Papp Clinical Research Inc., Waterloo

N8W 5W7

Windsor Clinical Research, Inc., Windsor

H2K 4L5

Innovaderm Research, Inc, Montreal

H3Z 2S6

Siena Medical Research, Montreal

G1V 4X7

Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ), Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Dermira, Inc.

INDUSTRY

NCT01936324 - A Safety, Tolerability and Preliminary Efficacy Study of DRM01B Topical Gel | Biotech Hunter | Biotech Hunter